Cerebral Venous Thrombosis as The Sole Presenting Manifestation of Human Immunodeficiency Virus and Hepatitis B Virus Co-Infection

Ajitava Dutta1, Ritwik Ghosh2, Alak Pandit1, Adrija Ray3, Dwaipayan Bhattacharya1, Arkaprava Chakraborty1, Uddalak Chakraborty1, Souvik Dubey1, Julián Benito-León*4,5,6

1Department of Neuromedicine, Bangur Institute of Neurosciences, Institute of Post Graduate Medical Education and Research & SSKM Hospital, Kolkata, West Bengal, India;
2Department of General Medicine, Burdwan Medical College, and Hospital, Burdwan, West Bengal, India;
3Department of General Medicine RG Kar Medical College, and Hospital, Kolkata, West Bengal, India;
4Department of Neurology, University Hospital “12 de Octubre”, Madrid, Spain;
5Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain;
6Department of Medicine, Complutense University, Madrid, Spain

Abstract

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Authors' contributions: AD collaborated in 1) the conception, organization, and execution of the research project; and 2) the writing of the first draft and the review and critique of the manuscript. RG collaborated in 1) the conception, organization, and execution of the research project; and 2) the writing of the first draft and the review and critique of the manuscript. AP collaborated in 1) the conception, organization, and execution of the research project; and 2) the review and critique of the manuscript. AR collaborated in 1) the conception, organization, and execution of the research project; and 2) the review and critique of the manuscript. DB collaborated in 1) the conception, organization, and execution of the research project; and 2) the review and critique of the manuscript. AC collaborated in 1) the conception, organization, and execution of the research project; and 2) the review and critique of the manuscript. UC collaborated in 1) the conception, organization, and execution of the research project; and 2) the review and critique of the manuscript. SD collaborated in 1) the conception, organization, and execution of the research project; and 2) the review and critique of the manuscript. JBL collaborated in 1) the conception, organization, and execution of the research project; and 2) the review and critique of the manuscript.

Competing interests: The authors declare no competing interests.

Disclosures:
Dr. Ajitava Dutta (ajitava.dutta.1990@gmail.com) reports no relevant disclosures.
Dr. Ritwik Ghosh (ritwikmed2014@gmail.com) reports no relevant disclosures.
Dr. Alak Pandit (dralakpandit@gmail.com) reports no relevant disclosures.
Dr. Adrija Ray (adrija.ray211@gmail.com) reports no relevant disclosures.
Dr. Dwaipayan Bhattacharya (dr.dwaipayan@gmail.com) reports no relevant disclosures.
Dr. Arkaprava Chakraborty (Thearka.chak@gmail.com) reports no relevant disclosures.
Dr. Uddalak Chakraborty (uddalakchakraborty@gmail.com) reports no relevant disclosures.
Dr. Souvik Dubey (dsouvik79@gmail.com) reports no relevant disclosures.
Dr. Julián Benito-León (jbenito67@gmail.com) reports no relevant disclosures.

Ethics approval and consent to participate: The patient signed informed consent to publish the case and the images.

Consent for publication: Yes.
**Background:** Cerebral venous thrombosis (CVT) following either human immunodeficiency virus (HIV) infection or hepatitis B virus (HBV) infection is a very rare condition. Moreover, it has never been reported as the presenting manifestation of HIV and HBV co-infection, even more so when the patient had a normal CD4 count and no demonstrable opportunistic infections. We aimed to report the first case of an adult Indian male, an intravenous drug abuser who developed CVT as the presenting manifestation of HIV-HBV co-infection.

**Methods:** Patient data were obtained from medical records from the Bangur Institute of Neurosciences, Institute of Post Graduate Medical Education and Research & SSKM Hospital, Kolkata, West Bengal, India.

**Results:** A 25-year-old male with a history of intravenous drug abuse and a normal CD4 count developed CVT as the presenting manifestation of HIV-HBV co-infection. His CD4 count was normal, and he had no demonstrable opportunistic infections. He had an uneventful recovery of the condition (CVT) following the institution of conventional anticoagulation therapy alongside anti-retroviral therapy.

**Conclusion:** Whether illicit drug abuse or HIV/HBV infection itself or all in combination led to this thrombotic event cannot be precisely established. Notwithstanding, we recommend serologic testing for HIV and HBV in patients suffering from CVT with high-risk behavior.

**Keywords**
HIV; HBV; Co-infection; Cerebral venous thrombosis

**INTRODUCTION**

The links between cerebral venous thrombosis (CVT) and head/neck and systemic infections are known, with recent-most addition to the list being coronavirus infectious disease of 2019 (COVID-19).1

Despite the advent of highly effective combination anti-retroviral therapy shifting the paradigms of HIV therapeutics, central nervous system disorders associated with HIV infection continue to represent a substantial societal, personal and economic burden.2 CVT is a less well-known neurological manifestation of HIV infection with apparently lower incidence.3–5 Several factors increase the risk of development of CVT in HIV-infected individuals, i.e., prothrombotic milieu (especially elevated homocysteine and low vitamin B12 levels), intravenous drug use, prolonged immobility in later stages of the full-blown disease, associated head/neck and systemic infections opportunistic infections with a predisposition for thrombogenesis, and reduced CD4 count.3–5

Viral hepatitis has been marked as a promoting factor for venous thromboembolism, including CVT, albeit rarely.6,7 However, hepatitis B virus (HBV) infection has rarely been associated with CVT development.8–11 Increased platelet activation and other means of thrombophilias have been proposed as the probable pathogenetic mechanisms in these cases.8–13
On the other hand, illicit drug use, taken through several routes, has also been linked to the development of CVT.\textsuperscript{14,15}

We herein report the first case of an adult male, an intravenous drug abuser, who developed CVT as the sole manifestation of HIV-HBV co-infection. His CD4 count was normal, and he had no demonstrable opportunistic infections. Whether illicit drug abuse or HIV/HBV infection or all in combination led to this thrombotic event cannot be precisely concluded. However, with conventional parenteral-followed-by-oral anticoagulation therapy his neurological deficits improved.

**RESULTS**

A 25-year-old right-handed Indian male was admitted to the emergency room with sudden-onset convulsions involving the right upper limb, right half of the face, and neck deviation towards the right side. The picture was followed by weakness of the right upper limb and deviation of the angle of the mouth towards the left side for the last day. He complained of dull-aching, holocranial headache for the last two weeks. He had no history of fever, vomiting, diarrhea, recent COVID-19 infection/vaccination, head/neck and systemic infections, visual disturbance, misalignment of eyes, head/neck trauma, arterial hypertension, diabetes mellitus, and thyroid and heart diseases. Neurological examination was only remarkable for the weakness of the right upper limb (MMRC grade 3/5) and upper motor neuron-type of right facial palsy with extensor right planter response. However, general examination revealed healed cut marks over the volar aspect of his left forearm suggestive of “tentative cuts” as well as a few punctuate scars with post-inflammatory changes over the forearm and cubital fossa, further confirmed by his caregivers to be marks of needle tracks as evidence of intravenous illicit drug use.

The oropharyngeal swab test for SARS-CoV-2 by qualitative real-time reverse-transcriptase–polymerase-chain-reaction assay was negative. A brain computed tomography (CT) scan revealed an intracerebral hematoma (ICH) over the left parietal region (Figure 1A). Magnetic resonance venography (MRV) with contrast showed superior and inferior sagittal sinus thrombosis with multiple collaterals (Figure 1B). Complete blood cell count, blood glucose, lipids profile, thyroid, hepatic, and kidney function tests were unremarkable. Protein C and S levels, anti-thrombin III, homocysteine, anti-phospholipid and anticroidilin antibodies, lupus anticoagulant, factor V Leiden mutation, vitamin B12, and D-dimer were normal. Antinuclear antibodies (ANA), ANA-profile, rheumatoid factor, cryoglobulins, and tests for vasculitides were negative. Serologies for hepatitis C and syphilis were negative but were reactive for HIV-1 and hepatitis B surface antigens (HBsAg). Anti-HBc-IgM was positive, and anti-HBs negative, suggesting acute HBV infection in an unvaccinated individual. His CD4 count was 529 cells/μL. Relevant tests ruled out head/neck and systemic infections.

The patient was started on intravenous unfractionated heparin followed by warfarin overlap with a target international normalized ratio (INR) of 2–3. He improved as his headache disappeared by the end of the first week of treatment and his right upper limb and right facial palsy weakness. He was discharged with warfarin (5 mg/day) with strict monitoring.
of INR. He was also prescribed tenofovir, dolutegravir, and lamivudine for treatment of HIV infection. Only strict monitoring with an assessment of HBV-DNA levels (half-yearly) and liver function tests (monthly) was advised for HBV infection.

DISCUSSION

No previous case whereby CVT was the presenting manifestation of HIV and HBV co-infection had been reported. However, there have been scarcely documented isolated cases/series whereby underlying HIV was unfurled by CVT or known serologically positive HIV patients without co-existing opportunistic neuro-infection(s) who developed CVT.\textsuperscript{3–5,17,18} Cryptococcal meningitis-associated CVT in HIV-infected patients has been a more common concern.\textsuperscript{19} On occasions, in a few previous reports/series of HIV-infected individuals with CVT (without opportunistic neuro-infections), hyperhomocysteinemia, low B12 levels, chronic alcoholism, and abnormal levels of protein S have been recorded.\textsuperscript{5,17,20} Now, whether these confounders are true contributing factors for the development of CVT or just mere epiphenomena remain elusive.\textsuperscript{21}

Different mechanisms have been proposed to explain the pathogenesis of CVT in HIV and HBV infection (Table 1). HIV infection can produce an acquired hypercoagulable state characterized by protein C, protein S, and anti-thrombin III deficit,\textsuperscript{22–26} especially when the CD4 count is low.\textsuperscript{24} Levels of several circulating thrombophilic/procoagulant factors, e.g., plasminogen activator inhibitor-1, tissue plasminogen activator, heparin cofactor-II, von-Willebrand factor, and the tissue factor (thromboplastin) may get elevated in people harboring HIV infection.\textsuperscript{22–26} Even anti-phospholipid antibodies might be found in HIV infection and might be a risk factor for the genesis of CVT.\textsuperscript{27} Kindred opportunistic infections, malignancies, and some anti-retroviral therapies (particularly the protease inhibitors) associated with HIV may also contribute to a thrombophilic state.\textsuperscript{22–26} Interestingly, a manifold increase in the risk of venous thromboembolic events among patients with HIV infection with intravenous drug abuse has been demonstrated.\textsuperscript{28} This holds special significance in our case, as our patient also had evidence of illicit drug use, particularly by intravenous route. It is difficult to ascertain whether HIV/HBV singly or in conjunction led to CVT. A complex interplay between HBV and other factors may tilt the delicate thrombosis/thrombolysis balance towards thrombosis.\textsuperscript{5–13} Cryoglobulinemia is commonly found during HIV disease, especially in hepatitis C virus co-infections.\textsuperscript{29} Again, cryoglobulinemia may predispose to hyperviscosity.\textsuperscript{30}

Conclusions

CVT can result from several infective and non-infective etiologies.\textsuperscript{1,31} However, HIV and HBV, alone or simultaneously, have rarely been attributed as precipitating factors of CVT. Thus, identifying the exact culprit(s) behind CVT in our patient seems to be a riddle arduous to solve. Notwithstanding, HIV and HBV testing should be performed in patients suffering from CVT with high-risk behavior(s). Lastly, although several reports of CVT following COVID-19 infection\textsuperscript{1,32} and even following COVID-19 vaccination\textsuperscript{33} have been gaining attention, evidence of causal association is still lacking. Still, we counseled the patient that if he had a choice, he could opt for COVAXIN instead.
Funding:

J. Benito-León is supported by the National Institutes of Health, Bethesda, MD, USA (NINDS #R01 NS39422), European Commission (grant ICT-2011-287739, NeuroTREMOR), the Ministry of Economy and Competitiveness (grant RTC-2015-3967-1, NetMD—platform for the tracking of movement disorder), and the Spanish Health Research Agency (grant FIS PI12/01602 and grant FIS PI16/00451).

Availability of data and materials:

The data supporting the findings of this study is available within the article.

References

1. Ghosh R, Roy D, Mandal A, et al. Cerebral venous thrombosis in COVID-19. Diabetes Metab Syndr. 2021;15(3):1039–1045. doi:10.1016/j.dsx.2021.04.026 [PubMed: 34015627]
2. Boissé L, Gill MJ, Power C. HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin. 2008;26(3):799–x. doi:10.1016/j.ncl.2008.04.002 [PubMed: 18657727]
3. Modi M, Singla V, Ahluwalia J, et al. HIV infection presenting as cerebral venous sinus thrombosis. Am J Emerg Med. 2012;30(3):517.e1517.e5173. doi:10.1016/j.ajem.2011.01.022
4. Mwita JC, Baliki K, Tema L. Cerebral venous sinus thrombosis in HIV-infected patients: report of 2 cases. Pan Afr Med J. 2013;16:4. Published 2013 Sep 4. doi:10.11604/pamj.2013.16.4.3252 [PubMed: 24570775]
5. Netravathi M, Jaychandran R, Bhat M, Christopher R, Satishchandra P. Profile of 26 HIV Seropositive individuals with Cerebral Venous Thrombosis. J Neurol Sci. 2017;378:69–74. doi:10.1016/j.jns.2017.04.034 [PubMed: 28566183]
6. Galli L, Gerdes VE, Guasti L, Squizzato A. Thrombosis Associated with Viral Hepatitis. J Clin Transl Hepatol. 2014;2(4):234–239. doi:10.14218/JCTH.2014.00031 [PubMed: 26357629]
7. Zis P, Kontogeorgi E, Karakalos D, Pavlopoulou D, Sevastianos VA. Cerebral venous thrombosis as an extrahepatic manifestation of acute anicteric hepatitis a infection. Case Rep Neurol Med. 2012;2012:120423. doi:10.1155/2012/120423
8. Pérez S, Casado I, García I, Gómez M, Ramírez JM, Luengo E. Infarto hemorrágico por trombosis del seno transverso como complicación de la cirrosis [Hemorrhagic infarct as a result of cerebral venous thrombosis as a complication of cirrhosis]. Rev Neurol. 1999;29(12):1355–1356. [PubMed: 10652778]
9. Felicio AC, Fukujima MM, Fiorot JA Jr, et al. Cerebral venous thrombosis and hepatitis: case report. Arq Neuropsiquiatr. 2006;64(4):1041–1042. doi:10.1590/s0004-282x2006000600033 [PubMed: 17221023]
10. Shan F, Gao C, Long Y, et al. Cerebral venous sinus thrombosis may be associated with hepatitis B virus infection: a preliminary finding. Neurol Res. 2015;37(6):510–513. doi:10.1179/1743132815Y.0000000003 [PubMed: 25591420]
11. Rao SM, Khardenavis S, Deshpande A, Pandi S. Case report of isolated vein of trolard thrombosis in an HBsAg-positive patient. Medical Journal of Dr. DY Patil University; 2014;1;7(2):222.
12. Nadir A, Amin A, Chalisa N, van Thiel DH. Retinal vein thrombosis associated with chronic hepatitis C: a case series and review of the literature. J Viral Hepat. 2000;7(6):466–470. doi:10.1046/j.1365-2893.2000.00245.x [PubMed: 11115059]
13. Zachou K, Liaskos C, Christodoulou DK, et al. Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I cofactor or features of antiphospholipid syndrome. Eur J Clin Invest. 2003;33(2):161–168. doi:10.1046/j.1365-2362.2003.01110.x [PubMed: 12588291]
14. Murthy BV, Wenstone R. Cerebral venous thrombosis associated with inhalational drug abuse. Rhinology. 1996;34(3):188–190. [PubMed: 8938893]
15. Burns H, Rich P, Al-memar AY. An unpleasant hit from cocaine: a case of cocaine-induced cerebral venous sinus thrombosis. Journal of Neurology, Neurosurgery and Psychiatry. 2012;1:83:A1.

16. Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review [published correction appears in Lancet Glob Health. 2017 Nov 15:]. Lancet Glob Health. 2017;5(12):e1192–e1207. doi:10.1016/S2214-109X(17)30375-3 [PubMed: 29074409]

17. Konin C, Adoh M, Adoubi A, et al. Thromboses veineuses inhabituelles révélatrices d’une infection par le virus de l’immunodéficience humaine et d’un déficit en protéine S. A propos de deux cas et revue de la littérature [Unusual venous thrombosis revealing a human immunodeficiency virus infection and a protein S deficiency. Two cases and literature review]. Rev Med Interne. 2008;29(6):508–511. doi:10.1016/j.revmed.2007.12.022 [PubMed: 18304701]

18. Rakhra A, Kiefer LE, Busireddy KR, Sankaraneni R. Cerebral Venous Sinus Thrombosis in an Immunocompetent HIV Patient. Cureus. 2021;13(3):e13694. Published 2021 Mar 4. doi:10.7759/cureus.13694 [PubMed: 33833915]

19. Okudo J, Civelli VF, Narang VK, et al. A Rare Case of *Cryptococcus gattii* Meningitis in Advanced HIV Disease, Sagittal Thrombosis, and Immune Reconstitution Syndrome, Resolved With Isavuconazonium. J Investig Med High Impact Case Rep. 2020;8:2324709620959880. doi:10.1177/2324709620959880 [PubMed: 32285297]

20. Modi M, Singla V, Aahuwalia J, et al. HIV infection presenting as cerebral venous sinus thrombosis. Am J Emerg Med. 2012;30(3):517.e1517.e5173. doi:10.1016/j.ajem.2011.01.022

21. Dillmon MS, Saag MS, Hamza SH, Adler BK, Marques MB. Unusual thromboses associated with protein S deficiency in patients with acquired immunodeficiency syndrome: case reports and review of the literature. AIDS Res Hum Retroviruses. 2005;21(9):753–756. doi:10.1089/aid.2005.21.753 [PubMed: 16218798]

22. Sule AA, Pandit N, Handa P, et al. Risk of Venous Thromboembolism in Patients Infected with HIV: A Cohort Study. Int J Angiol. 2013;22(2):95–100. doi:10.1055/s-0033-133866 [PubMed: 24436591]

23. Rokx C, Borjas Howard JF, Smit C, et al. Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. PLoS Med. 2020;17(5):e1003101. Published 2020 May 14. doi:10.1371/journal.pmed.1003101 [PubMed: 32407386]

24. Matta F, Yaekoub AY, Stein PD. Human immunodeficiency virus infection and risk of venous thromboembolism. Am J Med Sci. 2008;336(5):402–406. doi:10.1097/MAJ.0b013e31813816dd2fd [PubMed: 19011397]

25. Hooper WC, Phillips DJ, Ribeiro MJ, et al. Tumor necrosis factor-alpha downregulates protein S secretion in human microvascular and umbilical vein endothelial cells but not in the HepG-2 hepatoma cell line. Blood. 1994;84(2):483–489. [PubMed: 8025276]

26. Berger JR, Harris JO, Gregorios J, Norenberg M. Cerebrovascular disease in AIDS: a case-control study. AIDS. 1990;4(3):239–244. doi:10.1097/00002030-199003000-00010 [PubMed: 2350443]

27. Hassoun A, Al-Kadhimi Z, Cervia J. HIV infection and antiphospholipid antibody: literature review and link to the antiphospholipid syndrome. AIDS Patient Care STDS. 2004;18(6):333–340. doi:10.1089/1087291041444032 [PubMed: 15294083]

28. Rasmussen LD, Dybdal M, Gerstoft J, et al. HIV and risk of venous thromboembolism: a Danish nationwide population-based cohort study. HIV Med. 2011;12(4):202–210. doi:10.1111/j.1468-1293.2010.00869.x [PubMed: 20726905]

29. Genet P, Courdavault L, Wifaq B, Gerbe J. Symptomatic mixed cryoglobulinemia during HIV primary infection: a case report. Case reports in infectious diseases. Epub 2011 Nov 20.

30. Della Rossa A, Tavoni A, Bombardieri S. Hyperviscosity syndrome in cryoglobulinemia: clinical aspects and therapeutic considerations. Semin Thromb Hemost. 2003;29(5):473–477. doi:10.1055/s-2003-44555 [PubMed: 14631547]

31. Ghosh R, León-Ruiz M, Roy D, Naga D, Sardar SS, Benito-León J. Cerebral venous sinus thrombosis following Russell’s viper (Daboia russellii) envenomation: A case report and review
of the literature [published online ahead of print, 2022 Aug 27]. Toxicon. 2022;218:8–12. doi:10.1016/j.toxicon.2022.08.014 [PubMed: 36041514]

32. Roy D, Ghosh R, Dubey S, Dubey MJ, Benito-León J, Kanti Ray B. Neurological and Neuropsychiatric Impacts of COVID-19 Pandemic. Can J Neurol Sci. 2021;48(1):9–24. doi:10.1017/cjn.2020.173 [PubMed: 32753076]

33. Dutta A, Ghosh R, Bhattacharya D, et al. Anti-PF4 antibody negative cerebral venous sinus thrombosis without thrombocytopenia following immunization with COVID-19 vaccine in an elderly non-comorbid Indian male, managed with conventional heparin-warfarin based anticoagulation. Diabetes Metab Syndr. 2021;15(4):102184. doi:10.1016/j.dsx.2021.06.021 [PubMed: 34186376]
Figure 1:
Computed tomography scan of the brain reveals an intracerebral hematoma over the left parietal region (A). Magnetic resonance venography with contrast shows a superior and inferior sagittal sinus thrombosis with multiple collaterals (B).
Table 1:

Pathogenetic mechanisms of development of cerebral venous thrombosis in human immunodeficiency virus and hepatitis B infections.

| PATHOGENESIS                                      | PLAUSIBILITY IN OUR PATIENT                                      |
|---------------------------------------------------|-----------------------------------------------------------------|
| **HUMAN IMMUNODEFICIENCY VIRUS**                   |                                                                  |
| **Protein S deficiency**                           | Protein S values were within normal limits in our patient. Hence, this mechanism did not corroborate to development of cerebral venous thrombosis in our case. |
| The following factors may downregulate protein S synthesis in human immunodeficiency virus and thereby catalyze a procoagulant state: |                                                                  |
| • human immunodeficiency virus may infect the endothelium of the cerebral blood vessels and disrupt endothelial production of protein S |                                                                  |
| • Production of autoantibodies                     |                                                                  |
| • Release of tumor necrosis factor-a                |                                                                  |
| **Certain opportunistic infections**                | Not possible as in our patient, there was no opportunistic infection. |
| Microbial products and the inflammatory milieu tend to elevate pro-inflammatory lipids and inflammatory markers such as IL-6, TNF-α1, and C-reactive protein. The rise in tissue factor expression, thrombin, D-dimer, fibrinogen, and factor VIII levels are also observed. |                                                                  |
| **Anti-retroviral therapy, particularly antiproteases (by dysregulating endothelial and platelet function)** | Our patient was not on anti-retroviral therapy. Hence, this does not seem to be the possible mechanism. |
| **In the setting of profound immunodeficiency, the human immunodeficiency virus could itself be thrombogenic by the following mechanisms:** | CD4 counts in our patient were normal |
| • Elevation of von Willebrand factor                |                                                                  |
| • Heparin second cofactor deficiency                |                                                                  |
| **Presence of antiphospholipid antibodies**         | Not possible as testing for antiphospholipid antibodies yielded negative results. |
| **HEPATITIS B**                                    |                                                                  |
| • Increased mean platelet volume, which in turn is associated with increased platelet activation | It seems to be unlikely because of the average platelet count. |
| • Generation of antiphospholipid antibodies         | Not possible as testing for antiphospholipid antibodies yielded negative results. |